Interestingly, recent preclinical investigations have identified the natural compound, chlorotoxin, as a novel antigen which exhibits preferential binding to GBM tumours compared to normal brain tissues, mediated by the expression of MMP-2 on tumour cells [239]. This evidence concerns the gene MMP2 and glioblastoma.